Clinical Trial Update: Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating gefitinib for recurrent endometrial cancer (uterine corpus carcinoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Corpus Carcinoma

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Carcinoma | Phase 2 | Status: COMPLETED